On October 24, 2022 Guangzhou Maxinovel Pharmaceuticals reported that closed a $14 million Series C+ round to support its portfolio of eight small molecule targeted and immunotherapy candidates (Press release, Maxinovel Pharmaceiticals, OCT 24, 2022, View Source [SID1234622466]). Maxinovel’s lead product is a small molecule PD-L1 inhibitor that matched the efficacy of Durvalumab in a human PD-1 knock-in mice model. The company is developing products for hematological tumors, solid tumors and autoimmune diseases using its oral, radiotherapy imaging and transdermal platforms. The C+ round funds were raised from LAPAM Capital, Zhongxin Capital and Deyi Runrong Venture Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!